Menu
Fechar
hrs4r
 I want to donate

JAVIER ABEL MENÉNDEZ MENÉNDEZ

Metabolism and Cancer
Firma
JAVIER ABEL MENÉNDEZ-MENÉNDEZ
Position
Cap de Grup - R4
Group leader - R4
Projectes
Publicacions

Projectes

Precision Oncology in Girona

A therapeutic strategy to co-target brain metastasis-initiating and hyperlipidemia-driving mechanisms in lorlatinib-treated NSCLC

Codi oficial: Pfizer 2019 Joaquim Bosch Start date:05/07/2019 Data fi: 31/12/2025 Investigador/a principal: JOAQUIM BOSCH BARRERA, JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: PFIZER, S.L.U.
Metabolism and Cancer

Ayuda de personal Miquel Servet

Codi oficial: CP20/00003 Start date:01/01/2021 Data fi: 31/12/2025 Investigador/a principal: ELISABET CUYÀS NAVARRO, JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: INSTITUTO DE SALUD CARLOS III
Metabolism and Cancer

Ajuts per donar suport a les activitats dels grups de recerca de Catalunya (SGR-Cat 2021) - Metabolisme i càncer

Codi oficial: 2021 SGR 01507 Start date:01/01/2022 Data fi: 30/06/2025 Investigador/a principal: BEGOÑA MARTIN CASTILLO Organisme finançador: AGÈNCIA DE GESTIÓ UNIVERSITARIS I RECERCA
Metabolism and Cancer

Un nuevo enfoque de la actividad ácido graso sintasa como sistema de procesamiento de información en la oncología de precisión funcional

Codi oficial: PID2022-141955OB-I00 Start date:01/09/2023 Data fi: 31/08/2026 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: MINISTERIO DE ECONOMIA E INNOVACION

Publicacions

Steen TV, Espinoza I, Duran C, Casadevall G, Serrano-Hervás E, Cuyàs E, Verdura S, Kemble G, Kaufmann SH, McWilliams R, Osuna S, Billadeau DD, Menendez JA, Lupu R

Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer.

NEOPLASIA, 2025, 62, 101143-101143 dx.doi.org/10.1016/j.neo.2025.101143
López, J, Llop-Hernández, A, Verdura, S, Serrano-Hervás, E, Martinez-Balibrea, E, Bosch-Barrera, J, Teixidor, E, López-Bonet, E, Martin-Castillo, B, Sardanyés, J, Alarcón, T, Lupu, R, Cuyàs, E, Menendez, JA

Mitochondrial priming and response to BH3 mimetics in "one-two punch" senogenic-senolytic strategies

Cell Death Discovery, 2025, 11, 91-91 dx.doi.org/10.1038/s41420-025-02379-y
Espín, R, Medina-Jover, F, Sigüenza-Andrade, J, Farran-Matas, S, Mateo, FSigüenza, Figueras, A, Sanz, RT, Vicent, GP, Shabbir, A, Ruiz-Auladell, L, Racionero-Andrés, E, García, I, Baiges, A, Franco-Luzón, L, Martínez-Tebar, A, Pardo-Cea, MA, Martínez-Iniesta, M, Wang, XC, Cuyàs, E, Menendez, JA, Lopez-Cerda, M, Muñoz, P, Richaud, I, Raya, A, Fabregat, I, Villanueva, A, Serrat, X, Cerón, J, Alemany, M, Guix, I, Herencia-Ropero, A, Serra, V, Krishnan, R, Mekhail, K, Hakem, R, Bruna, J, Barcellos-Hoff, MH, Viñals, F, Aytes, A, Pujana, MA

Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment

Nar Cancer, 2025, 7 dx.doi.org/10.1093/narcan/zcaf007
Jiménez-Franco A, Castañé H, Martínez-Navidad C, Placed-Gallego C, Hernández-Aguilera A, Fernández-Arroyo S, Samarra I, Canela-Capdevila M, Arenas M, Zorzano A, Hernández-Alvarez MI, Castillo DD, Paris M, Menendez JA, Camps J, Joven J

Metabolic adaptations in severe obesity: Insights from circulating oxylipins before and after weight loss

CLINICAL NUTRITION, 2024, 43, 246-258 dx.doi.org/10.1016/j.clnu.2023.12.002
Menendez JA, Cuyàs E, Encinar JA, Steen TV, Verdura S, Llop-Hernández À, López J, Serrano-Hervás E, Osuna S, Martin-Castillo B, Lupu R

Fatty acid synthase (FASN) signalome: A molecular guide for precision oncology

MOLECULAR ONCOLOGY, 2024, 18, 479-516 dx.doi.org/10.1002/1878-0261.13582
Verdura S, Encinar JA, Gratchev A, Llop-Hernández À, López J, Serrano-Hervás E, Teixidor E, López-Bonet E, Martin-Castillo B, Micol V, Bosch-Barrera J, Cuyàs E, Menendez JA

Silibinin is a suppressor of the metastasis-promoting transcription factor ID3

Phytomedicine, 2024, 128, 155493-155493 dx.doi.org/10.1016/j.phymed.2024.155493
Cuyàs E, Pedarra S, Verdura S, Pardo MA, Espin Garcia R, Serrano-Hervás E, Llop-Hernández À, Teixidor E, Bosch-Barrera J, López-Bonet E, Martin-Castillo B, Lupu R, Pujana MA, Sardanyès J, Alarcón T, Menendez JA

Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity.

Cell Death Discovery, 2024, 10, 417-417 dx.doi.org/10.1038/s41420-024-02184-z
Teixidor-Vilà E, Trallero J, Puigdemont M, Vidal-Vila A, Hernandez-Martínez A, Sais E, Sabaté-Ortega J, Verdura S, Menendez JA, Bosch-Barrera J, Sanvisens A, Marcos-Gragera R

Lung cancer survival trends and prognostic factors: A 26-year population-based study in Girona Province, Spain.

LUNG CANCER, 2024, 197, 107995-107995 dx.doi.org/10.1016/j.lungcan.2024.107995
Teixidor-Vilà, E, Verdura, S, JA Encinar, Llop-Hernández À, Sais, E, Hernández Martínez A, ROMERA, A., Brunet JM, Martin-Castillo B, Lopez-Bonet, E, Bosch-Barrera, J, Cuyàs, E, Menendez, JA

1039P Discovery of a novel inhibitor of PD-L1 maturation that overcomes adaptive resistance to cancer immunotherapy

ANNALS OF ONCOLOGY, 2024, 35, 697-697 dx.doi.org/10.1016/j.annonc.2024.08.1097
Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Oncotarget, 2023, 14, 668-668 dx.doi.org/10.18632/oncotarget.28471

Formulari de contacte

About IDIBGI!

 menu